Perception of Use of Herbal and Orthodox Medicines in Parts of Abuja: A Pilot Study.

This study assessed respondents’ perception on packaging, affordability, availability, efficacy, and safety of use of herbal and orthodox medicine in the treatment of common diseases in Abuja. Structured questionnaires were administered to elicit information from 200 residents selected from five locations through a purposive sampling method and data were analyzed using descriptive statistics. Orthodox medicines were rated higher than herbal medicine in term of preference, packaging, first-aid and uses. While in terms of affordability, adverse effect, natural and efficacious to the body, the respondents preferred herbal medicine. About Seventy percentage chose orthodox medicine as their first drug of choice while 28% preferred herbal medicine as their first drug of choice. 72.96% of the respondents have used herbal medicines without any side effect while 10.77% had experienced adverse effects from its use and 16.33% claimed they have never used herbal medicines for treatment before. The differences in the means of attributes of herbal and orthodox medicines were not statistically significant at P>0.05. The information obtained is in agreement with WHO statement that over 80% of the world’s population depends on traditional medicine for its primary health care.

Pharmacokinetics of Chloroquine and Metronidazole in Rats.

The single oral dose pharmacokinetics of chloroquine (5mg/kg body weight) and metronidazole (7.5mg/kg body weight) were studied in rats’ serum. Chloroquine and metronidazole concentrations were measured using high-performance liquid chromatography (HPLC) method developed earlier in our laboratory. The data were fitted into a WinNonlin standard non-compartmental programme. The Maximum serum concentration Cmax (μg/ml) of chloroquine was 5.70 ± 1.41 while that of metronidazole was 3.13  0.30, Time to peak concentration tmax was 1.00  0.00 (h) and that of metronidazole was 0.83 ± 0.27, Volume of distribution Vd (L) 1.33 ± 0.26 for metronidazole 2.39  0.28; Elimination half-life t1/2 (h) 10.05 ± 3.01 for metronidazole 4.05  0.46. The values were comparable with the works of other authors. Compounds that show very high activity in -vitro may not have in vivo activity, or may be highly toxic using in- vivo models due to undesirable pharmacokinetic properties, and toxicity may result from formation of reactive metabolites. This study assures the quality of the brands of the drugs and encouraged the use of animal model in determining pharmacokinetic properties especially in drug design.